Trevi Therapeutics Shares Are Trading Higher After the Company Announced Positive Outcomes for the Treatment of Patients From Its Chronic Cough Phase 2b CORAL Trial.

BenzingaDec 12 08:14 ET

Sector Update: Health Care

MT Newswires2minutes ago

Trevi Therapeutics Price Target Raised to $7.50/Share From $6.00 by HC Wainwright & Co.

Dow Jones33minutes ago · Ratings

Trevi Therapeutics Is Maintained at Buy by HC Wainwright & Co.

Dow Jones33minutes ago · Ratings

Trevi Therapeutics Phase IIb Update a Major De-risking Event, Says B. Riley

TipRanks34minutes ago

H.C. Wainwright Ups Trevi Therapeutics Target After 'Best-case' for CORAL

TipRanks44minutes ago